Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Theratechnologies stock price, quote, forecast and news

TH.TO
CA88338H1001
915439

Price

1.35
Today +/-
+0.04
Today %
+2.92 %
P

Theratechnologies stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Theratechnologies stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Theratechnologies stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Theratechnologies stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Theratechnologies's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Theratechnologies Stock Price History

DateTheratechnologies Price
8/8/20241.35 undefined
8/7/20241.31 undefined
8/6/20241.35 undefined
8/2/20241.36 undefined
8/1/20241.41 undefined
7/31/20241.43 undefined
7/30/20241.42 undefined
7/29/20241.46 undefined
7/26/20241.45 undefined
7/25/20241.45 undefined
7/24/20241.46 undefined
7/23/20241.53 undefined
7/22/20241.53 undefined
7/19/20241.57 undefined
7/18/20241.52 undefined
7/17/20241.53 undefined
7/16/20241.58 undefined
7/15/20241.54 undefined
7/12/20241.44 undefined
7/11/20241.43 undefined

Theratechnologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Theratechnologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Theratechnologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Theratechnologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Theratechnologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Theratechnologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Theratechnologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Theratechnologies’s growth potential.

Theratechnologies Revenue, EBIT and net profit per share

DateTheratechnologies RevenueTheratechnologies EBITTheratechnologies Net Income
2029e227.68 M undefined0 undefined54.2 M undefined
2028e186.05 M undefined158.62 M undefined38.1 M undefined
2027e143.81 M undefined86.99 M undefined20.92 M undefined
2026e115.54 M undefined32.74 M undefined8.16 M undefined
2026e120.25 M undefined-31.19 M undefined-6.06 M undefined
2025e100.79 M undefined19.63 M undefined3.55 M undefined
2024e90.65 M undefined9.73 M undefined124,638.24 undefined
202381.76 M undefined-10.63 M undefined-23.96 M undefined
202280.06 M undefined-39.91 M undefined-47.24 M undefined
202169.82 M undefined-25.24 M undefined-31.73 M undefined
202066.05 M undefined-18.87 M undefined-22.67 M undefined
201963.22 M undefined-8.51 M undefined-12.5 M undefined
201845.22 M undefined-3.67 M undefined-4.7 M undefined
201732.91 M undefined-7.62 M undefined-14.16 M undefined
201627.92 M undefined2.97 M undefined310,000 undefined
201523.85 M undefined3.29 M undefined1.25 M undefined
20146.14 M undefined-11.74 M undefined-9.61 M undefined
20137.38 M undefined-7.42 M undefined-3.96 M undefined
201213.54 M undefined-4.13 M undefined-13.91 M undefined
201115.12 M undefined-18.27 M undefined-17.95 M undefined
201030.81 M undefined6.44 M undefined8.63 M undefined
200915.11 M undefined-14.49 M undefined-13.11 M undefined
20082.52 M undefined-38.74 M undefined-45.87 M undefined
20072.89 M undefined-34.55 M undefined-34.61 M undefined
20061.45 M undefined-22.79 M undefined-22.79 M undefined
200513.54 M undefined-4.12 M undefined-11.8 M undefined
20042.02 M undefined-17.48 M undefined-17.44 M undefined

Theratechnologies Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2026e2027e2028e2029e
00112252213122153015137623273245636669808190100120115143186227
----100.00-150.00-60.00-550.00-92.31100.00-650.00100.00-50.00-13.33-46.15-14.29283.3317.3918.5240.6340.004.764.5515.941.2511.1111.1120.00-4.1724.3530.0722.04
---100.00100.00100.00100.00------100.00100.0033.3361.5442.8650.0086.9681.4878.1368.8958.7357.5866.6766.2576.54-------
0001225000000153058332022253137384653620000000
-3-4-3-3-5-8-15-18-17-4-22-34-38-146-18-4-7-1132-7-3-8-18-25-39-10919-3132861580
---300.00-300.00-250.00-400.00-300.00-900.00-850.00-30.77-2,200.00-1,700.00-1,900.00-93.3320.00-120.00-30.77-100.00-183.3313.047.41-21.88-6.67-12.70-27.27-36.23-48.75-12.3510.0019.00-25.8327.8360.1484.95-
-3-4-3-3317-9-23-17-11-22-34-45-138-17-13-3-910-14-4-12-22-31-47-2303-68203854
-33.33-25.00--200.00466.67-152.94155.56-26.09-35.29100.0054.5532.35-71.11-161.54-312.50-23.53-76.92200.00-111.11---71.43200.0083.3340.9151.61-51.06---300.00-233.33150.0090.0042.11
14.8516.8318.3520.725.4828.3730.6130.8234.4835.5343.3352.5857.4260.3161.3260.7360.9861.0161.0163.1765.8173.4775.9476.9376.9923.0923.8126.330000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Theratechnologies Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Theratechnologies is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
7.6710.415.118.732.825.130.315.111.715.830910.927.83.21.712.811.55.717.948.740.620.840.3533.0740.39
2.60.10.10.30.30.50.40.40.30.20.30.50001.31.10.423.457.5119.510.99.2610.6612.8
0.60.60.70.71.20.91.40.80.70.91.61.41.71.60.50.80.50.10.1000.100.62.31.671.690.75
2.30.10.200.50.71.30.81.31.70.72.102.14.210.112.910.49.39.59.17.211.120.925.129.1419.696.07
0.100.10.30.20.40.30.50.20.40.30.40.60.61.22.61.10.51.11.31.31.92.94.55.711.498.273.29
13.27.811.516.420.935.328.532.817.614.918.734.411.315.233.71817.312.415.325.721.134.673.776.164.891.9173.3763.3
2.90.30.40.411.74.84.11.91.81.41.71.11.2110.40.30.10.1000.11.13.52.853.091.98
0000.827.443.542.928.431.122.516.23128.549.135.132.81910.6002.97.75.20.60000
0000000000.10.10000000000000001.680
0.10.30.40.55.59.713.57.46.66.98.27.52.200000.213.211.615.316.932.239.731.923.8315.0112.5
0000000000000000000000000000
00.10.10.10.10.10.10.10.200000000000000000.621.790
30.70.91.8345561.34039.831.325.940.231.850.336.133.819.411.113.311.718.224.637.541.435.427.321.5714.47
16.28.512.418.254.990.389.872.857.446.244.674.643.165.569.851.836.723.528.637.439.359.2111.2117.5100.2119.2194.9477.77
23.522.329.237.569.269.189107.6131.3133.5155.6238.9217.9264.5272.2275.2282.5264.6246.1217.8217254.9286.8287287.3335.75338.75363.93
0002000.10.11.92.23.14.84.76.47.68.18.27.87.36.410.611.78.810.812.112.8418.8123.18
-11.8-15.3-18.2-22.6-30.7-13-23.5-53.5-80.1-93.7-119.7-177.4-185.4-231.3-229.1-248.1-268.3-255.2-246.5-210.4-208.9-233.2-265-277.5-300.1-335.25-382.65-408.66
00000000000-0.30.31.20.60.50.40.20.11.11.40.14.44.544.412.520.68
0000000000000000000000000000
11.771116.938.556.165.654.253.142396637.540.851.335.722.817.4714.920.133.53524.83.317.76-22.57-20.87
2.80.90.91.12.655.95.54.245.78.643.62.44.71.50.51.62.42.35.425.813.117.515.5312.896.99
000000000000002.521.82.64.66.54.811.5017.416.824.1424.7419.95
0.100.10000000001.58.26.74.63.21.30.50.50.91.713.22.54.9511.3812.65
300000000000000000000000000000
0000000000000000003.23.33.53.603.45.10.4665.277.71
3.20.911.12.655.95.54.245.78.65.511.811.611.36.54.49.912.711.522.226.837.141.945.08114.2847.29
1.30000000000000000011.89.46.63.549.255.35556.281.4551.26
000000.92000000000000000000000
00.60.50.313.813.52.42.90000013757.31.600.51.3000.300.090.110.08
1.30.60.50.313.814.44.42.90000013757.31.611.89.97.93.549.255.65556.381.5551.35
4.51.51.51.416.419.410.38.44.245.78.65.524.818.616.313.8621.722.619.425.77692.796.9101.45115.8398.64
16.28.512.518.354.975.575.962.657.34644.774.64365.669.95236.623.428.737.539.559.2111117.5100.2119.2193.2677.77
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Theratechnologies provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Theratechnologies's financial health and stability.

Assets

Theratechnologies's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Theratechnologies must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Theratechnologies after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Theratechnologies's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-3-4-3-3317-9-23-17-11-22-34-46-138-17-13-3-910-14-4-12-22-31-47
0000001211015000001111478812
0000000000000000000000-10000
0000000000020-1-1-62-210-28-1-3-608
0000-9-26-620701118-4-3-4-10126356811
000000000000000000000003334
000000-10000-1-100000000000000
-2-3-3-3-4-8-15-19-16-3-20-29-4042-27-15-7-75210-3-13-14-14
00000-1-40000000000000-10-19-3000
13-4-5-29-30-418541-2011-1221214772-9-15-904-128
14-4-5-28-29019641-1911-1121214772-8-15934-129
000000000000000000000000000
0000000000000000000-4-3-446-3-4-510
60893611901201955288000008018000472
508835391801101852278000003-31347-6-7349
0000-138-1000-1-2-100000000-10-3-3-7-3
000000000000000000000000000
300000-100002-2124-24-10011-10037-10-1573
-3.04-3.82-4.04-3.54-5.64-9.7-19.05-20.23-17.31-4.05-20.53-30.34-40.794.542.4-27.8-15.67-7.56-8.095.620.831.81-19.48-7.01-13.58-14.64-15.68
000000000000000000000000000

Theratechnologies stock margins

The Theratechnologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theratechnologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theratechnologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Theratechnologies's sales revenue. A higher gross margin percentage indicates that the Theratechnologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Theratechnologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Theratechnologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Theratechnologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Theratechnologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Theratechnologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Theratechnologies Margin History

Theratechnologies Gross marginTheratechnologies Profit marginTheratechnologies EBIT marginTheratechnologies Profit margin
2029e75.99 %0 %23.81 %
2028e75.99 %85.26 %20.48 %
2027e75.99 %60.49 %14.55 %
2026e75.99 %28.34 %7.07 %
2026e75.99 %-25.93 %-5.04 %
2025e75.99 %19.47 %3.52 %
2024e75.99 %10.73 %0.14 %
202375.99 %-13 %-29.3 %
202267.17 %-49.85 %-59 %
202166.69 %-36.14 %-45.44 %
202057.9 %-28.57 %-34.32 %
201958.75 %-13.46 %-19.77 %
201870.43 %-8.12 %-10.39 %
201778.76 %-23.15 %-43.03 %
201682.02 %10.64 %1.11 %
201586.62 %13.79 %5.24 %
201463.52 %-191.21 %-156.51 %
201350.81 %-100.54 %-53.66 %
201262.7 %-30.5 %-102.73 %
201138.69 %-120.83 %-118.72 %
201098.54 %20.9 %28.01 %
2009100 %-95.9 %-86.76 %
200875.99 %-1,537.3 %-1,820.24 %
200775.99 %-1,195.5 %-1,197.58 %
200675.99 %-1,571.72 %-1,571.72 %
200575.99 %-30.43 %-87.15 %
200475.99 %-865.35 %-863.37 %

Theratechnologies Stock Sales Revenue, EBIT, Earnings per Share

The Theratechnologies earnings per share therefore indicates how much revenue Theratechnologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Theratechnologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Theratechnologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Theratechnologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Theratechnologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Theratechnologies Revenue, EBIT and net profit per share

DateTheratechnologies Sales per ShareTheratechnologies EBIT per shareTheratechnologies Earnings per Share
2029e9.41 undefined0 undefined2.24 undefined
2028e7.69 undefined0 undefined1.57 undefined
2027e5.94 undefined0 undefined0.86 undefined
2026e4.77 undefined0 undefined0.34 undefined
2026e4.97 undefined0 undefined-0.25 undefined
2025e4.16 undefined0 undefined0.15 undefined
2024e3.75 undefined0 undefined0.01 undefined
20233.11 undefined-0.4 undefined-0.91 undefined
20223.36 undefined-1.68 undefined-1.98 undefined
20213.02 undefined-1.09 undefined-1.37 undefined
20200.86 undefined-0.25 undefined-0.29 undefined
20190.82 undefined-0.11 undefined-0.16 undefined
20180.6 undefined-0.05 undefined-0.06 undefined
20170.45 undefined-0.1 undefined-0.19 undefined
20160.42 undefined0.05 undefined0 undefined
20150.38 undefined0.05 undefined0.02 undefined
20140.1 undefined-0.19 undefined-0.16 undefined
20130.12 undefined-0.12 undefined-0.06 undefined
20120.22 undefined-0.07 undefined-0.23 undefined
20110.25 undefined-0.3 undefined-0.3 undefined
20100.5 undefined0.11 undefined0.14 undefined
20090.25 undefined-0.24 undefined-0.22 undefined
20080.04 undefined-0.67 undefined-0.8 undefined
20070.05 undefined-0.66 undefined-0.66 undefined
20060.03 undefined-0.53 undefined-0.53 undefined
20050.38 undefined-0.12 undefined-0.33 undefined
20040.06 undefined-0.51 undefined-0.51 undefined

Theratechnologies business model

Theratechnologies Inc is a pharmaceutical company based in Canada, specializing in the development, manufacturing, and marketing of innovative therapy options for oncology and HIV/AIDS. The company has established itself as a player in the global healthcare market in recent years, thanks to its precise focus on niche markets and international expansion. Theratechnologies is one of the most popular companies on Eulerpool.com.

Theratechnologies SWOT Analysis

Strengths

Theratechnologies Inc. is a biopharmaceutical company focused on developing innovative therapeutic products for specialty markets. With its deep expertise in research and development, the company has a strong portfolio of drugs addressing various medical conditions.

One of Theratechnologies' key strengths lies in its robust pipeline, which includes potential breakthrough treatments for HIV-associated lipodystrophy, oncology-related cachexia, and non-alcoholic steatohepatitis. These developments put the company in a favorable position to cater to unmet medical needs and capture a significant market share.

Furthermore, Theratechnologies benefits from strategic partnerships and collaborations with renowned academic institutions and industry leaders. These collaborations not only provide access to additional resources and expertise but also enhance the company's reputation and credibility.

Weaknesses

Despite its strengths, Theratechnologies faces some weaknesses that may hinder its growth potential. One of the primary weaknesses is its relatively limited product portfolio, as the company is heavily dependent on a few key drugs.

Additionally, Theratechnologies operates within a highly regulated industry, which creates challenges in terms of compliance with complex regulations and potential delays in obtaining approvals for new drugs.

Another weakness to note is the intense competition in the biopharmaceutical sector. Theratechnologies must continually innovate and differentiate itself to maintain its market position and stay ahead of competitors.

Opportunities

Theratechnologies has significant opportunities to capitalize on. The global biopharmaceutical market is experiencing strong growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technologies.

Through its innovative pipeline, Theratechnologies can explore new markets and expand its product offerings, thereby capturing a more extensive patient base and generating higher revenues.

Furthermore, collaborations and partnerships with other pharmaceutical companies or research institutions can open doors to accessing new markets, sharing costs, and combining expertise and resources, leading to mutual benefits.

Threats

Theratechnologies faces various threats that may impact its business. One of the significant threats is the risk of patent expirations, which can lead to generic competition and a decline in market share and profitability.

Moreover, the biopharmaceutical industry is susceptible to regulatory uncertainties, including changes in drug pricing policies and intellectual property regulations. Such uncertainties can significantly affect Theratechnologies' financial performance and market position.

Additionally, Theratechnologies must remain vigilant about emerging technologies and competitors who may disrupt the market or develop alternative treatment options that could render its products less effective or obsolete. Continuous monitoring of the competitive landscape is crucial to seize opportunities and mitigate these threats.

Theratechnologies Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Theratechnologies historical P/E ratio, EBIT, and P/S ratio.

Theratechnologies shares outstanding

The number of shares was Theratechnologies in 2023 — This indicates how many shares 26.332 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Theratechnologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Theratechnologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Theratechnologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Theratechnologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Theratechnologies Stock splits

In Theratechnologies's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Theratechnologies.

Theratechnologies latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.02 USD0.02 USD (216.28 %)2024 Q2
3/31/2024-0.13 USD-0.1 USD (20.76 %)2024 Q1
12/31/2023-0.25 USD-0.08 USD (68.3 %)2023 Q4
9/30/2023-0.3 USD-0.03 USD (89.87 %)2023 Q3
6/30/2023-0.26 USD-0.4 USD (-55.34 %)2023 Q2
3/31/2023-0.4 USD-0.44 USD (-11.25 %)2023 Q1
12/31/2022-0.3 USD-0.36 USD (-19.17 %)2022 Q4
9/30/2022-0.49 USD-0.32 USD (35.28 %)2022 Q3
6/30/2022-0.39 USD-0.96 USD (-145.27 %)2022 Q2
3/31/2022-0.29 USD-0.36 USD (-24.83 %)2022 Q1
1
2
3
4
5
...
10

Theratechnologies list of shareholders

%
Name
Stocks
Change
Date
9.14 % Morgan Stanley & Co. LLC2,212,3813,60012/31/2023
37.68 % Investissement Québec9,118,184012/31/2023
3.75 % Worth Venture Partners, LLC906,557710,55112/31/2023
19.84 % Soleus Capital Master Fund, L.P.4,801,3782,470,00010/31/2023
19.84 % Soleus Capital Management, L.P.4,801,376012/31/2023
11.62 % AIGH Capital Management, LLC.2,812,745-1,011,31812/31/2023
11.08 % Nantahala Capital Management, LLC2,682,2282,682,22812/31/2023
0.57 % Molson (Andrew Thomas)137,50022,50011/30/2023
0.53 % Osaic Holdings, Inc.128,054-96,86112/31/2023
0.47 % National Bank of Canada113,37844,82512/31/2023
1
2
3
4
5
...
9

Theratechnologies Executives and Management Board

Mr. Paul Levesque59
Theratechnologies President, Chief Executive Officer, Director (since 2020)
Compensation 2.53 M USD
Dr. Christian Marsolais60
Theratechnologies Senior Vice President, Chief Medical Officer
Compensation 837,165 USD
Mr. John Leasure58
Theratechnologies Global Commercial Officer
Compensation 820,968 USD
Mr. Philippe Dubuc56
Theratechnologies Chief Financial Officer, Senior Vice President
Compensation 820,114 USD
Mr. Jocelyn Lafond55
Theratechnologies General Counsel, Company Secretary (since 2022)
Compensation 576,532 USD
1
2
3

Theratechnologies Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Pfizer Stock
Pfizer
SupplierCustomer0,61-0,09-0,290,39-0,610,17
Walgreens Boots Alliance Stock
Walgreens Boots Alliance
SupplierCustomer0,490,20-0,040,520,440,74
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,220,20-0,34-0,86-0,920,15
Cigna Stock
Cigna
SupplierCustomer0,030,24-0,24-0,81-0,740,35
McKesson Stock
McKesson
SupplierCustomer-0,040,19-0,42-0,87-0,940,03
Syneos Health A Stock
Syneos Health A
SupplierCustomer-0,32-0,14-0,100,780,640,75
UDG Healthcare PLC Stock
UDG Healthcare PLC
SupplierCustomer-0,370,03-0,03-0,86-0,87-
Cardinal Health Stock
Cardinal Health
SupplierCustomer-0,57-0,15-0,29-0,80-0,430,13
Jubilant Pharmova Stock
Jubilant Pharmova
SupplierCustomer-0,79-0,42-0,200,750,870,24
1

Most common questions regarding Theratechnologies

What values and corporate philosophy does Theratechnologies represent?

Theratechnologies Inc, a leading pharmaceutical company, represents a core set of values and corporate philosophy. With a strong commitment to innovation and patient-centricity, Theratechnologies focuses on developing groundbreaking therapies to address unmet medical needs. The company's corporate philosophy revolves around fostering a culture of integrity, collaboration, and social responsibility. By prioritizing scientific excellence, Theratechnologies demonstrates its dedication to improving the lives of patients worldwide. With its unwavering dedication to research and development, Theratechnologies continues to shape the future of healthcare by delivering innovative treatments and providing hope for patients and their families.

In which countries and regions is Theratechnologies primarily present?

Theratechnologies Inc is primarily present in Canada and the United States.

What significant milestones has the company Theratechnologies achieved?

Theratechnologies Inc has achieved significant milestones in its journey. The company successfully developed and gained regulatory approval for its innovative HIV treatment, EGRIFTA®. This medication helps manage excess abdominal fat in HIV-infected patients. Theratechnologies Inc also expanded its global presence by securing marketing authorizations in multiple countries. The company further strengthened its product portfolio by launching Trogarzo®, a breakthrough treatment for multidrug-resistant HIV-1. Additionally, Theratechnologies Inc has established strategic partnerships with renowned organizations, enabling greater market reach and research collaborations. These milestones exemplify the company's commitment to advancing the field of HIV therapeutics and improving patient outcomes.

What is the history and background of the company Theratechnologies?

Theratechnologies Inc is a Canadian pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 1993, Theratechnologies has continuously focused on discovering treatments for unmet medical needs. The company has made significant advancements in the field of HIV-associated lipodystrophy, with its flagship product Egrifta being approved by regulatory authorities in the United States, Europe, and Canada. Theratechnologies is committed to delivering effective therapies that improve patients' quality of life. With a strong dedication to research and development, the company has established itself as a key player in the pharmaceutical industry.

Who are the main competitors of Theratechnologies in the market?

The main competitors of Theratechnologies Inc in the market include companies such as Gilead Sciences, Inc., AbbVie Inc., and Novartis AG.

In which industries is Theratechnologies primarily active?

Theratechnologies Inc is primarily active in the pharmaceutical industry.

What is the business model of Theratechnologies?

The business model of Theratechnologies Inc. is focused on developing and commercializing innovative therapies for people living with serious medical conditions. Theratechnologies specializes in targeted peptide-based therapies and has expertise in developing products for the treatment of HIV-associated lipodystrophy and human growth hormone deficiency. The company strives to address unmet medical needs through research, development, and commercialization of safe and effective therapies. Theratechnologies aims to improve the quality of life for patients by bringing innovative treatments to market and collaborating with healthcare professionals.

What is the P/E ratio of Theratechnologies 2024?

The Theratechnologies P/E ratio is 284.6.

What is the P/S ratio of Theratechnologies 2024?

The Theratechnologies P/S ratio is 0.39.

What is the AlleAktien quality score of Theratechnologies?

The AlleAktien quality score for Theratechnologies is 5/10.

What is the revenue of Theratechnologies 2024?

The expected Theratechnologies revenue is 90.65 M USD.

How high is the profit of Theratechnologies 2024?

The expected Theratechnologies profit is 124,638.24 USD.

What is the business model of Theratechnologies

Theratechnologies Inc. is a biopharma company based in Montreal, Canada, specializing in the research, development, manufacturing, and marketing of medications for the treatment of immune system and metabolic diseases. The company is divided into three business segments: therapeutics, diagnostics, and partner programs. The therapeutics division focuses on the development, manufacturing, and marketing of medications used in chronic immune system and metabolic diseases, such as HIV infections, obesity, and diabetes. Therapeutic products from Theratechnologies aim to improve healthcare by enhancing the quality of life for patients with chronic illnesses. Theratechnologies has also gained expertise in the biotherapeutic development and manufacturing of antibodies and is working on the development of antibodies for the treatment of autoimmune diseases. The diagnostics business of Theratechnologies is dedicated to the production of diagnostic tests for the detection of HIV infections. These tests have played a crucial role in monitoring therapy for HIV patients and the treatment of HIV infections. Theratechnologies is also involved in the development of partner programs aimed at expanding the company's product range. These programs involve innovative product development, collaborations, and licensing agreements with other companies and institutions. Theratechnologies has a number of significant product developments and patents that support the growth of the company. Some of the key products of the company include: - EGRIFTA®: This medication is used for the treatment of excess fat tissue in HIV patients. EGRIFTA® stimulates hormone production and reduces fat tissue. - Trogarzo®: Trogarzo® is an anti-HIV medication used in patients who are resistant to other HIV medications. This medication prevents the binding of HIV to the T-cell receptor and the entry of the virus into the cell. - TH1902: This medication is a combination of a cytotoxic agent and a carrier protein. TH1902 targets cancer cells by selectively delivering the cytotoxic agent to the tumor. Theratechnologies has become a key player in the biopharma industry by continuously investing in research and development of new products and forming partnerships with other industry leaders. This business model has facilitated the company's growth in recent years and provides a solid foundation for a promising future.

What is the Theratechnologies dividend?

Theratechnologies pays a dividend of 0 USD distributed over payouts per year.

How often does Theratechnologies pay dividends?

The dividend cannot currently be calculated for Theratechnologies or the company does not pay out a dividend.

What is the Theratechnologies ISIN?

The ISIN of Theratechnologies is CA88338H1001.

What is the Theratechnologies WKN?

The WKN of Theratechnologies is 915439.

What is the Theratechnologies ticker?

The ticker of Theratechnologies is TH.TO.

How much dividend does Theratechnologies pay?

Over the past 12 months, Theratechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theratechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Theratechnologies?

The current dividend yield of Theratechnologies is .

When does Theratechnologies pay dividends?

Theratechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theratechnologies?

Theratechnologies paid dividends every year for the past 0 years.

What is the dividend of Theratechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theratechnologies located?

Theratechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theratechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theratechnologies from 8/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/9/2024.

When did Theratechnologies pay the last dividend?

The last dividend was paid out on 8/9/2024.

What was the dividend of Theratechnologies in the year 2023?

In the year 2023, Theratechnologies distributed 0 USD as dividends.

In which currency does Theratechnologies pay out the dividend?

The dividends of Theratechnologies are distributed in USD.

All fundamentals about Theratechnologies

Our stock analysis for Theratechnologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theratechnologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.